



ROCK[®] Platform

Activating innate and adaptive immunity to fight cancer

Pioneering immune cell engagers



Affimed N.V.

Our mission at Affimed (Nasdaq: AFMD) is to create novel therapeutic options for patients suffering from cancer and other life-threatening diseases. With our differentiated approach to arm and deploy the body’s innate and adaptive immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies.

Affimed’s ROCK[®] Platform - Redirected Optimized Cell Killing


Affimed’s unique ROCK[®] platform enables the generation of first-in-class tetravalent, multi-specific immune cell engagers. This proprietary platform supports innate and adaptive drug development (NK and T cell engagers) and, based on its modularity, allows for antibody engineering of highly customizable immune cell engagers tailored to different indications and settings. A prerequisite for redirected optimized cell killing enabling the development of effective therapies is the ability to utilize different antibody formats and immune effector cell types. Affimed’s ROCK[®] platform addresses this need.

Affimed’s ROCK[®] Platform

- Suitable for the development of both NK and T cell engagers, thus employing both innate and adaptive immunity to fight cancer
- Generates antibody candidates tailored to different indications and settings
- Supports the potential for tetravalent and multi-specific formats
- Allows for the generation of engagers with variable pharmacokinetic (PK) profiles
- Enables the generation of immune cell engagers with favorable manufacturing properties

ROCK[®]'s modularity is built on a toolbox of proprietary formats and long-standing engineering know-how: A combination of competencies essential for the construction of novel, potent and custom immune cell engagers.

Partnerships with Industry, Academia and Advocacy Groups



Redirected Optimized Cell Killing (ROCK®)


Redirecting innate and adaptive immune cells with multi-specific antibodies to achieve optimized killing of malignant cells is a powerful novel approach for therapy of cancer patients.

Affimed's Long-Standing Expertise

Affimed has long-standing expertise in drug development of differentiated immune cell engagers and protein engineering, enabling the design of a novel class of tetravalent, multi-specific formats.

ROCK® Platform

A versatile platform of immune cell engagers based on a proprietary toolbox and modularity



Affimed Highlights

- ✓ Lead product candidate: AFM13 most advanced NK cell engager in clinical development
 - Positive efficacy data as monotherapy in HL and in CD30-positive lymphoma
 - Encouraging efficacy in combination with Keytruda® (best response preliminary data: ORR of 89% and CR rate of 28%)
 - Suitable for combinations with checkpoint inhibitors, adoptive NK cell transfer or cytokines
- ✓ Differentiated T cell-based approach with two molecules in clinical development based on Affimed's platform
- ✓ Diverse pipeline of clinical and preclinical assets based on tetravalent bispecific antibody formats

Management Team

Proven track record in biotech, pharma, product development and finance

Adi Hoess, PhD, CEO

- CEO since 2011
- Led AFMD IPO in 2014
- Co-founded MorphoSys

Florian Fischer, PhD, CFO

- CFO since 2005
- Led AFMD IPO in 2014
- Deutsche Bank and KPMG

Wolfgang Fischer, PhD, COO

- Joined 2017 from Sandoz (Novartis)
- Global Head Program&Project Mgmt
- Regional Medical Director Hematology

Leila Alland, MD, CMO

- Joined 2018 from Tarveda Therapeutics
- Oncology lead at AZ, BMS and Novartis

Martin Treder, PhD, CSO

- Joined 2015 from CT Atlantic (Swiss I/O)
- Co-founder U3 Pharma (targeted cancer therapeutics)

Denise Mueller, Head Comm. Strat/BD

- Joined 2016 from Pfizer
- US & global marketing, Pfizer and Wyeth

Affimed
Technologiepark
Im Neuenheimer Feld 582
69120 Heidelberg, Germany

Contact Us
info@affimed.com
www.affimed.com

